Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Microbix BiosystemsMBXBF 55 EV-to-EBITDA is -13.37 as of Jul. 29, 2026. GuruFocus rates MBXBF with a GF Score™ of 55/100 and a GF Value™ of $0.18 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 407 Biotechnology companies, Microbix Biosystems ranks worse than 245700% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Microbix Biosystems's enterprise value is $28.82 Mil.
Microbix Biosystems's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.16 Mil. Therefore, Microbix Biosystems's EV-to-EBITDA for today is -13.37.
The historical rank and industry rank for Microbix Biosystems's EV-to-EBITDA or its related term are showing as below:
MBXBF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -97.09 Med: 10.51 Max: 271.91
Current: -13.37
During the past 13 years, the highest EV-to-EBITDA of Microbix Biosystems was 271.91. The lowest was -97.09. And the median was 10.51.
MBXBF's EV-to-EBITDA is ranked worse than 100% of 407
companies
in the Biotechnology industry
Industry Median: 11.7
vs MBXBF: -13.37
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Microbix Biosystems's PE Ratio (TTM) for today is calculated as:
Microbix Biosystems's share price for today is $0.22.
Microbix Biosystems's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Microbix Biosystems's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MBXBF vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Microbix Biosystems's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microbix Biosystems EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Microbix Biosystems's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Microbix Biosystems's EV-to-EBITDA falls into.
Microbix Biosystems's current Enterprise Value is $28.82 Mil.
Microbix Biosystems's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.16 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Microbix Biosystems (MBXBF) has a EV-to-EBITDA of -13.37 as of Jul. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Microbix Biosystems. According to the industry distribution chart, Microbix Biosystems ranks #999999 out of 407 companies in the Biotechnology industry.
Is Microbix Biosystems' EV-to-EBITDA too high?
Microbix Biosystems' current EV-to-EBITDA is -13.37. Based on the distribution chart, Microbix Biosystems ranks #999999 out of 407 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Microbix Biosystems has a GF Score™ of 55/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Microbix Biosystems' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Microbix Biosystems ranks #999999 out of 407 companies for EV-to-EBITDA. This places Microbix Biosystems in the lower half of its industry. The industry median EV-to-EBITDA is 11.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.70, based on 407 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Microbix Biosystems. For the Biotechnology industry, the median EV-to-EBITDA is 11.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Microbix Biosystems's current EV-to-EBITDA is -13.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microbix Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Microbix Biosystems (MBXBF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.18, compared to a current price of $0.22 — trading 22.2% above its estimated fair value. The current EV-to-EBITDA is -13.37. Microbix Biosystems' overall GF Score™ is 55/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Microbix Biosystems (MBXBF), the current EV-to-EBITDA is -13.37 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Microbix Biosystems (MBXBF) Overvalued in 2026?
Based on GuruFocus' analysis, Microbix Biosystems stock appears to be overvalued.
The current stock price of $0.22 is trading 22.2% above its estimated GF Value™ of $0.18.
GuruFocus considers Microbix Biosystems to be Modestly Overvalued.
Key valuation signals for MBXBF:
EV-to-EBITDA: -13.37
GF Value™: $0.18 vs. price of $0.22 (22.2% above fair value)
No single metric tells the full story. See the MBXBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Microbix Biosystems Inc develops biological products and technologies. There are two operating segments: The development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows, and viral transport medium to enable collection of patient test samples; and the development and commercialization of novel and proprietary products or technologies such as Kinlytic. Geographically, it derives a majority of revenue from North America and also operates in Europe and other foreign countries.
55GF Score
Get the complete analysis for MBXBF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBXBF has been successfully added to your 
